A discordant falsely elevated beta human chorionic gonadotropin (bhcg) patient sample result was obtained on a dimension vista 1500 system.The discordant result was reported to the physician(s) who questioned the result.The same sample was then reprocessed on an alternate atellica im 1300 system, and a non-siemens system, and lower bhcg results, considered correct were obtained.Additionally, a qualitative kit testing was performed for the same patient sample, and a negative result was obtained.The lower reprocessed result from the non-siemens system was reported and the other reprocessed result was made known to the physician(s).No corrected report was issued.There are no known reports of patient intervention or adverse health consequences due to the discordant falsely elevated beta human chorionic gonadotropin (bhcg) result.
|
Additional information (03-mar-2022): siemens healthcare diagnostics headquarters support center (hsc) concluded the investigation of the event.Hsc requested the customer send siemens the patient sample for internal investigation.Due to insufficient volume, no patient sample was provided.Hsc reviewed the instrument data and the information provided by the customer.Hsc concluded that the data provided is consistent with a heterophilic antibody indication in the instructions for use (ifu) for dimension vista beta human chorionic gonadotropin (bhcg) assay.The cause of the event was determined to be the potential presence of heterophilic antibodies or non-specific binding (nsb) interference.A potential product issue was not identified.The bhcg ifu states: "patient samples may contain heterophilic antibodies that could react in immunoassays to give falsely elevated or depressed results.This assay has been designed to minimize interference from heterophilic antibodies.Nevertheless, complete elimination of this interference from all patient specimens cannot be guaranteed.A test result that is inconsistent with the clinical picture and patient history should be interpreted with caution." the device is performing within specifications.No further evaluation is required.Section h6 has been updated to reflect the hsc investigation.Initial mdr 2517506-2022-00028 was filed on 04-feb-2022.
|